Two-Punch combo aims to wipe out leukemia, offering hope for treatment breaks
NCT ID NCT03708003
Summary
This trial tested a two-drug combination (ibrutinib and venetoclax) for adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to prior treatment. The goal was to see if using the drugs together could achieve a deep remission, potentially allowing patients to take a break from continuous medication. The study enrolled 30 participants and was designed to carefully manage risks, starting with one drug before adding the second.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IOSI - Ospedale San Giovanni
Bellinzona, 6501, Switzerland
-
Inselspital
Bern, 3010, Switzerland
-
Kantonsspital Aarau
Aarau, CH-5001, Switzerland
-
Kantonsspital Graubünden
Chur, 7000, Switzerland
-
Kantonsspital Liestal
Liestal, CH-4410, Switzerland
-
Kantonsspital Münsterlingen
Münsterlingen, 8596, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
Luzerner Kantonsspital
Lucerne, 6000, Switzerland
-
Spital STS AG Thun
Thun, 3600, Switzerland
-
Universitätsspital Basel
Basel, 4031, Switzerland
-
Universitätsspital Zürich
Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.